Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The new definition of pulmonary hypertension

M. M. Hoeper
European Respiratory Journal 2009 34: 790-791; DOI: 10.1183/09031936.00056809
M. M. Hoeper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Despite the progress that has been made in the field of pulmonary hypertension (PH) 1–3, there is no unifying and globally accepted definition of the condition. The first official haemodynamic definition of PH was proposed at the First World Symposium on Pulmonary Hypertension which took place 1973 in Geneva, Switzerland as a World Health Organization (WHO)-sponsored meeting 4. This conference was triggered by the previous epidemic of PH associated with the appetite suppressant aminorex 5. As such, the focus of that meeting was primary pulmonary hypertension (PPH), as compared to the other forms of PH. After a long and sometimes heated debate the consensus was to define PPH by a mean pulmonary artery pressure (P̄pa) >25 mmHg at rest or >30 mmHg during exercise in the presence of a pulmonary capillary wedge pressure (Ppcw) ≤15 mmHg.

This definition was later extended to other forms of pulmonary arterial hypertension (PAH) 6. It stood the test of time for >30 yrs, but was challenged during the Fourth World Symposium on Pulmonary Hypertension, which took place 2008 in Dana Point, CA, USA. There were several reasons for this: 1) the old definition did not take into account other forms of PH; 2) the threshold of P̄pa >25 mmHg at rest does not reflect the upper limit of normal; 3) clinically relevant PH can be present, despite the P̄pa being <25 mmHg at rest; 4) the cut-off value of 30 mmHg during exercise was arbitrarily chosen and not supported by published data; and 5) PH is often present in conjunction with elevated Ppcw levels.

Some of these points are addressed in a paper by Kovacs et al. 7 published in the present issue of the European Respiratory Journal. In preparation for the Dana Point meeting, they performed a comprehensive review of the literature published since 1947 in English, German or French language searching for right heart catheterisations performed in healthy individuals. Altogether, they were able to identify data obtained from 1,187 individuals in 47 studies. A meta-analysis of these data showed that the normal P̄pa at rest is 14.3±3.3 mmHg. These values are virtually age-independent. Following the customary approach to define an upper level of normal as the mean plus two standard deviations, the upper level of normal for the P̄pa at rest would be 20 mmHg. However, provided that the Ppa is normally distributed, one in 40 healthy people will be above this threshold, i.e. 25,000 per million population. Even if the threshold is increased to 25 mmHg, the theoretical prevalence of individuals above this level would still be far beyond the known prevalence of PAH. Conversely, some studies indicate that even P̄pa >17–20 mmHg may be associated with a poor prognosis, especially in patients with chronic lung diseases 8–11. As is often the case in medicine, there exists a grey zone where a given value can be considered high, normal or already pathological, depending on the clinical context.

Of equal importance, the findings by Kovacs et al. 7 challenge the exercise component of the old PH definition. The problem with the 1973 WHO consensus was that the cut-off level of 30 mmHg during exercise was not supported by evidence. Kovacs et al. 7 show that, in younger persons aged <50 yrs, P̄pa of 35 mmHg can be considered normal during sub-maximal or maximal exercise. More importantly, in contrast to the Ppa at rest, the Ppa during exercise is largely age-dependent, presumably as a result of increasing stiffness of the left ventricle and the pulmonary vessels. P̄pa >30 mmHg during mild exercise is seen in ∼50% of apparently healthy subjects aged >50 yrs, and P̄pa up to 45 mmHg during exercise appear to be normal in this population. Thus, with the previous definition many individuals were incorrectly labelled as pulmonary hypertensive that in fact had simply a physiological exercise response. Taking into account all these variables, it seems impossible to come up with a solid definition of PH during exercise. Further research is ongoing in this field to generate the data that are needed to move forward in this important area of pulmonary vascular disease 12, 13.

The consequences of the findings by Kovacs et al. 7 were intensively discussed at the Fourth World Symposium on Pulmonary Hypertension in Dana Point and it was decided to abandon the exercise criterion. With regard to the definition of PH at rest, it was proposed to introduce the term “borderline PH” for patients with P̄pa 20–25 mmHg, but this term was eventually rejected, as it was felt that patients presenting with Ppa in this range should be further studied before being labelled with a diagnosis of PH. Thus, in the proceedings of the Dana Point meeting, the new haemodynamic definition of PH will be a P̄pa at rest ≥25 mmHg 14. This definition, which covers all forms of PH, will be adopted by the revised joint PH guidelines of the European Society of Cardiology and the European Respiratory Society, in which PH will be divided into pre-capillary and post-capillary forms, based on whether mean Ppcw is ≤15 or >15 mmHg, respectively 15, 16.

The revised haemodynamic definition of PH constitutes an improvement over the old definition, since it takes into account recent data and has broader applicability. Abandoning the exercise criterion is justified by the findings of Kovacs et al. 7 and it will prevent many false diagnoses of PH, as well as unjustified therapies. Limiting the current PH definition to a P̄pa at rest ≥25 mmHg is also comprehensible for the time being. All treatment studies performed so far in the field of PH have included only patients fulfilling this criterion. Milder forms of PH, i.e. resting Ppa 20–25 mmHg, are usually found among patients with underlying lung or heart disease, and medical therapies for these forms of PH have not been sufficiently studied. Eventually, with the broadening of our knowledge, the PH definition may have to be revised again.

Kovacs et al. 7 are to be commended for their invaluable contribution and it is likely that their manuscript will serve as a reference paper for a very long time.

Statement of interest

A statement of interest for M.M. Hoeper can be found at www.erj.ersjournals.com/misc/statements.dtl

    • © ERS Journals Ltd

    References

    1. ↵
      Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31:407–414.
      OpenUrlAbstract/FREE Full Text
    2. Wilkins MR, Wharton J, Grimminger F, et al. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008;32:198–209.
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:801–901.
      OpenUrl
    4. ↵
      Hatano S, Strasser T. Primary Pulmonary Hypertension: Report on a WHO Meeting, Geneva 15–17 October 1973. Geneva, World Health Organization, 1975
    5. ↵
      Bass O, Gurtner HP. [Evolution of primary vascular pulmonary hypertension following ingestion of aminorex fumarate (Menocil). Preliminary communication]. Schweiz Med Wochenschr 1973;103:1794
      OpenUrlPubMedWeb of Science
    6. ↵
      Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243–2278.
      OpenUrlFREE Full Text
    7. ↵
      Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888–894.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31:1357–1367.
      OpenUrlAbstract/FREE Full Text
    9. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371–1385.
      OpenUrlAbstract/FREE Full Text
    10. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193–1198.
      OpenUrlCrossRefPubMedWeb of Science
    11. ↵
      Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007;131:650–656.
      OpenUrlCrossRefPubMedWeb of Science
    12. ↵
      Oudiz RJ, Rubin LJ. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation 2008;118:2120–2121.
      OpenUrlFREE Full Text
    13. ↵
      Tolle JJ, Waxman AB, Van Horn TL, et al. Exercise-induced pulmonary arterial hypertension. Circulation 2008;118:2183–2189.
      OpenUrlAbstract/FREE Full Text
    14. ↵
      Badesch DB, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl., S55–S66
    15. ↵
      Galie N, Hoeper MM, Humbert M, et al. Guidelines on the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; In press
    16. ↵
      Galie N, Hoeper MM, Humbert M, et al. Guidelines on the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; In press
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 34 Issue 4 Table of Contents
    European Respiratory Journal: 34 (4)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    The new definition of pulmonary hypertension
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    The new definition of pulmonary hypertension
    M. M. Hoeper
    European Respiratory Journal Oct 2009, 34 (4) 790-791; DOI: 10.1183/09031936.00056809

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    The new definition of pulmonary hypertension
    M. M. Hoeper
    European Respiratory Journal Oct 2009, 34 (4) 790-791; DOI: 10.1183/09031936.00056809
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Nintedanib in chILD: a small step
    • GM-CSF targeting in COVID-19
    • EBAP: reflections on 20 years of CME in respiratory medicine
    Show more Editorials

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society